 WALTHAM, Mass., June 28, 2021 PRNewswire -- Syndax Pharmaceuticals, Inc. Syndax, the Company or we Nasdaq: SNDX, a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration FDA has granted Fast Track Designation FTD to SNDX-5613 for the treatment of adult and pediatric patients with relapsed or refractory acute leukemias harboring a mixed lineage leukemia rearranged MLLr or nucleophosmin NPM1 mutation. 